| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 23 | 2024 | 1688 | 3.050 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2023 | 2636 | 3.040 |
Why?
|
| Lung Neoplasms | 28 | 2024 | 1660 | 2.900 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2023 | 3157 | 2.060 |
Why?
|
| Selection, Genetic | 6 | 2024 | 152 | 2.040 |
Why?
|
| Genome, Human | 15 | 2020 | 1272 | 1.770 |
Why?
|
| Melanoma | 7 | 2024 | 943 | 1.730 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 862 | 1.730 |
Why?
|
| Mutation, Missense | 13 | 2024 | 875 | 1.580 |
Why?
|
| Codon, Nonsense | 3 | 2022 | 131 | 1.480 |
Why?
|
| Prostatic Neoplasms | 11 | 2017 | 1547 | 1.450 |
Why?
|
| Gene Expression Profiling | 10 | 2019 | 1711 | 1.240 |
Why?
|
| Neoplasms | 7 | 2020 | 2794 | 1.130 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 668 | 1.080 |
Why?
|
| Genes, Neoplasm | 2 | 2019 | 80 | 0.990 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2023 | 1893 | 0.920 |
Why?
|
| Gene Frequency | 6 | 2022 | 724 | 0.920 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 287 | 0.780 |
Why?
|
| X Chromosome | 1 | 2023 | 338 | 0.760 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 350 | 0.750 |
Why?
|
| Computational Biology | 6 | 2015 | 810 | 0.750 |
Why?
|
| Scleroderma, Systemic | 2 | 2019 | 119 | 0.730 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 180 | 0.730 |
Why?
|
| Biological Evolution | 5 | 2015 | 223 | 0.670 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 1497 | 0.650 |
Why?
|
| Mutation | 8 | 2024 | 5842 | 0.640 |
Why?
|
| Genetic Variation | 6 | 2020 | 1502 | 0.640 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 333 | 0.640 |
Why?
|
| Humans | 74 | 2024 | 125195 | 0.600 |
Why?
|
| Models, Statistical | 3 | 2019 | 471 | 0.540 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2020 | 1016 | 0.540 |
Why?
|
| RNA Splicing | 3 | 2014 | 226 | 0.500 |
Why?
|
| Genomics | 2 | 2014 | 1499 | 0.490 |
Why?
|
| Blood | 1 | 2015 | 103 | 0.490 |
Why?
|
| Gene Expression | 2 | 2018 | 1561 | 0.470 |
Why?
|
| Exons | 4 | 2014 | 798 | 0.470 |
Why?
|
| Alleles | 5 | 2020 | 1614 | 0.470 |
Why?
|
| Crossing Over, Genetic | 4 | 2001 | 50 | 0.460 |
Why?
|
| Genes, p53 | 2 | 2005 | 212 | 0.450 |
Why?
|
| Carcinogenesis | 1 | 2017 | 333 | 0.440 |
Why?
|
| Logistic Models | 7 | 2022 | 1810 | 0.420 |
Why?
|
| Environmental Exposure | 1 | 2015 | 220 | 0.410 |
Why?
|
| Introns | 1 | 2014 | 300 | 0.410 |
Why?
|
| Male | 49 | 2024 | 61524 | 0.410 |
Why?
|
| Algorithms | 5 | 2016 | 1629 | 0.390 |
Why?
|
| Meiosis | 7 | 2001 | 112 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 2018 | 160 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2024 | 668 | 0.380 |
Why?
|
| Lung | 4 | 2023 | 1496 | 0.360 |
Why?
|
| Recombination, Genetic | 4 | 2001 | 447 | 0.360 |
Why?
|
| Case-Control Studies | 15 | 2024 | 3300 | 0.360 |
Why?
|
| Cryptorchidism | 4 | 2012 | 37 | 0.360 |
Why?
|
| Genotype | 14 | 2016 | 2564 | 0.360 |
Why?
|
| CpG Islands | 4 | 2023 | 323 | 0.360 |
Why?
|
| Receptors, Nicotinic | 5 | 2012 | 154 | 0.350 |
Why?
|
| Oncogenes | 2 | 2022 | 167 | 0.350 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 666 | 0.350 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 2512 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 120 | 0.330 |
Why?
|
| Genes, Essential | 1 | 2009 | 40 | 0.320 |
Why?
|
| Genetics, Population | 3 | 2017 | 188 | 0.320 |
Why?
|
| Databases, Nucleic Acid | 2 | 2008 | 70 | 0.320 |
Why?
|
| Disease | 1 | 2010 | 129 | 0.320 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1527 | 0.310 |
Why?
|
| DNA Methylation | 3 | 2024 | 1007 | 0.310 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 1276 | 0.290 |
Why?
|
| Chromosomes | 3 | 2000 | 198 | 0.280 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 51 | 0.280 |
Why?
|
| Organ Specificity | 2 | 2019 | 428 | 0.270 |
Why?
|
| Smoking | 8 | 2024 | 1051 | 0.260 |
Why?
|
| Telomerase | 3 | 2019 | 160 | 0.260 |
Why?
|
| Adenocarcinoma | 6 | 2020 | 1026 | 0.260 |
Why?
|
| Homozygote | 4 | 2001 | 547 | 0.250 |
Why?
|
| Female | 31 | 2024 | 66803 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2019 | 1506 | 0.240 |
Why?
|
| Point Mutation | 1 | 2006 | 348 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2893 | 0.230 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2010 | 292 | 0.220 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2003 | 16 | 0.220 |
Why?
|
| Heterozygote | 4 | 2020 | 671 | 0.210 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 296 | 0.200 |
Why?
|
| Odds Ratio | 3 | 2022 | 1258 | 0.200 |
Why?
|
| Homeodomain Proteins | 2 | 2002 | 548 | 0.200 |
Why?
|
| Prognosis | 10 | 2024 | 4641 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 414 | 0.200 |
Why?
|
| Nucleotides | 1 | 2022 | 92 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 2048 | 0.190 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2020 | 96 | 0.180 |
Why?
|
| Chromosome Mapping | 5 | 2012 | 1078 | 0.180 |
Why?
|
| Conserved Sequence | 1 | 2022 | 291 | 0.180 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 470 | 0.180 |
Why?
|
| Proteins | 3 | 2018 | 1036 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.180 |
Why?
|
| Risk Factors | 16 | 2020 | 10312 | 0.180 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.180 |
Why?
|
| Chromosome Inversion | 2 | 1991 | 73 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 546 | 0.170 |
Why?
|
| Middle Aged | 21 | 2024 | 26938 | 0.170 |
Why?
|
| Open Reading Frames | 2 | 2014 | 211 | 0.170 |
Why?
|
| Genetic Association Studies | 2 | 2022 | 779 | 0.160 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2019 | 30 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 203 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 1329 | 0.160 |
Why?
|
| Mammals | 1 | 2000 | 257 | 0.160 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 141 | 0.160 |
Why?
|
| Aged | 16 | 2024 | 19881 | 0.150 |
Why?
|
| Mucins | 1 | 2019 | 75 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2018 | 66 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 756 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 1438 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 149 | 0.140 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 16 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 211 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2018 | 172 | 0.140 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 309 | 0.140 |
Why?
|
| Testis | 3 | 2012 | 410 | 0.130 |
Why?
|
| Linear Models | 1 | 2019 | 683 | 0.130 |
Why?
|
| Mice | 12 | 2012 | 17637 | 0.130 |
Why?
|
| Karyotyping | 6 | 2000 | 323 | 0.130 |
Why?
|
| Finasteride | 1 | 2016 | 20 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 657 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2014 | 652 | 0.130 |
Why?
|
| Phenotype | 7 | 2018 | 4263 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 837 | 0.120 |
Why?
|
| Models, Genetic | 4 | 2008 | 760 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2012 | 33 | 0.120 |
Why?
|
| Prostatectomy | 1 | 2016 | 344 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 248 | 0.110 |
Why?
|
| Inflammation | 2 | 2012 | 1448 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 604 | 0.110 |
Why?
|
| Alternative Splicing | 2 | 2007 | 352 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2523 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 416 | 0.100 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 6 | 0.100 |
Why?
|
| DNA Transposable Elements | 1 | 1993 | 177 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 290 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 207 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 319 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 142 | 0.100 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 23 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 173 | 0.090 |
Why?
|
| Software | 1 | 2016 | 683 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 188 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2012 | 398 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 19 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2016 | 493 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 76 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 1968 | 0.090 |
Why?
|
| Animals | 14 | 2012 | 34238 | 0.080 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2010 | 74 | 0.080 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 103 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 2397 | 0.080 |
Why?
|
| beta Catenin | 1 | 2010 | 204 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 1112 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2010 | 201 | 0.080 |
Why?
|
| Genes, Overlapping | 1 | 2008 | 7 | 0.080 |
Why?
|
| Survival Rate | 2 | 2012 | 2064 | 0.080 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 58 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 686 | 0.070 |
Why?
|
| Disease Progression | 2 | 2013 | 2064 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 163 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6604 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 354 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1288 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4536 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2174 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 576 | 0.070 |
Why?
|
| Spermatocytes | 1 | 1986 | 23 | 0.070 |
Why?
|
| Adult | 8 | 2024 | 29639 | 0.060 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 105 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 425 | 0.060 |
Why?
|
| PAX6 Transcription Factor | 2 | 2002 | 37 | 0.060 |
Why?
|
| Paired Box Transcription Factors | 2 | 2002 | 74 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1203 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2002 | 1290 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2056 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 816 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 468 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2002 | 404 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 233 | 0.060 |
Why?
|
| Genetic Markers | 3 | 1993 | 603 | 0.060 |
Why?
|
| Eye Proteins | 2 | 2002 | 218 | 0.060 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2004 | 21 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3072 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 70 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 613 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 39 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 53 | 0.050 |
Why?
|
| Haplotypes | 3 | 2011 | 522 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1396 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 3891 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1700 | 0.050 |
Why?
|
| Relaxin | 1 | 2002 | 15 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 261 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 125 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16344 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 294 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 4821 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 657 | 0.050 |
Why?
|
| Gene Deletion | 3 | 2012 | 789 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 1986 | 559 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 399 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 897 | 0.040 |
Why?
|
| Eye | 1 | 2002 | 227 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2002 | 813 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2012 | 230 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3348 | 0.040 |
Why?
|
| Jews | 1 | 2020 | 32 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 126 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 552 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 695 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 483 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 557 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 557 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 510 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 678 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2018 | 46 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1021 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 573 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 9056 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 474 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 1266 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2020 | 678 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1605 | 0.030 |
Why?
|
| HapMap Project | 1 | 2016 | 13 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2821 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 351 | 0.030 |
Why?
|
| Transgenes | 2 | 2010 | 336 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 696 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 58 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 419 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 272 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 285 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3091 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 302 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 1991 | 138 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4405 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 320 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 316 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 462 | 0.030 |
Why?
|
| Texas | 2 | 2012 | 3588 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2016 | 469 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1637 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 298 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 781 | 0.020 |
Why?
|
| Sperm Count | 1 | 2012 | 79 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 21 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 401 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 135 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 34 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2002 | 391 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 594 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 436 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 19355 | 0.020 |
Why?
|
| Muscle Development | 1 | 2010 | 71 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2016 | 643 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 880 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2002 | 767 | 0.020 |
Why?
|
| Actins | 1 | 2012 | 346 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2823 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 187 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 447 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1806 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 794 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1585 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 263 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2012 | 263 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2312 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 663 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 735 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 114 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2715 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 2298 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 535 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 453 | 0.020 |
Why?
|
| 11-Hydroxycorticosteroids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 1005 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 308 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 946 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1986 | 152 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 1460 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1434 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8228 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5176 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1898 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 3102 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 12507 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2004 | 242 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 121 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 14022 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 132 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 309 | 0.010 |
Why?
|
| Glycine | 1 | 2002 | 168 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1002 | 0.010 |
Why?
|
| Plasmids | 1 | 2002 | 513 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 55 | 0.010 |
Why?
|
| Pigmentation | 1 | 2001 | 35 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 487 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 1069 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 12396 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 1102 | 0.010 |
Why?
|
| Infertility | 1 | 2001 | 78 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 658 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 676 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2001 | 170 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 762 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 811 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1757 | 0.010 |
Why?
|
| Child | 1 | 2018 | 24407 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1608 | 0.010 |
Why?
|
| Diet | 1 | 2004 | 1140 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 4395 | 0.010 |
Why?
|
| Siberia | 1 | 1988 | 4 | 0.000 |
Why?
|
| Animals, Wild | 1 | 1988 | 26 | 0.000 |
Why?
|